A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Subjects will receive product as described in the sipuleucel-T approved label. The registry will be strictly observational and thus no additional clinical visits or laboratory tests will be conducted beyond normal clinical practice. Investigators will be asked to record information that becomes available in the normal course of clinical management.
Inclusion Criteria:
Exclusion Criteria:
Goodyear, Arizona 85338, United States
Scottsdale, Arizona 85258, United States
Los Angeles, California 90024, United States
Orange, California 92868, United States
Oxnard, California 93030, United States
Sacramento, California 95816, United States
New Britain, Connecticut 06052, United States
Washington D.C., District of Columbia 20060, United States
Lakeland, Florida 33805, United States
Atlanta, Georgia 30322, United States
South Bend, Indiana 46601, United States
Shreveport, Louisiana 71105, United States
Brownstown, Michigan 48183, United States
Columbia, Missouri 65203, United States
Lincoln, Nebraska 68510, United States
Lincoln, Nebraska 68516, United States
Lebanon, New Hampshire 03756, United States
Morristown, New Jersey 07962, United States
The Bronx, New York 10461, United States
Cary, North Carolina 27518, United States
New Bern, North Carolina 28562, United States
Raleigh, North Carolina 27607, United States
Raleigh, North Carolina 27614, United States
Sioux Falls, South Dakota 57105, United States
Beaumont, Texas 77702-1449, United States
Brookfield, Wisconsin 53045, United States